Outcomes following negative prostate biopsy for patients with persistent disease after radiotherapy for prostate cancer.
Reads0
Chats0
TLDR
Patients with PSA recurrence and a negative post-radiation biopsy have a high chance of persistent local disease, progression, and death from prostate cancer.Abstract:
PURPOSE: When faced with biochemical recurrence after definitive radiotherapy for prostate cancer, clinicians must determine whether the recurrence is local or systemic. Post radiotherapy prostate biopsies to detect persistent local disease are difficult to interpret histopathologically and are subject to sampling error. Our study examines outcomes for patients with a negative prostate biopsy performed for rising prostate-specific antigen (PSA) levels after prostate radiation. MATERIALS AND METHODS: We performed a retrospective review of 238 prostate cancer patients with a negative biopsy following definitive radiotherapy. Seventy-five of these patients had biochemical recurrence at the time of biopsy. A negative biopsy was defined as the absence of prostate cancer without radiation-treatment effect in the specimen. RESULTS: Patients underwent biopsy at a mean of 41 months after the completion of radiation. They had a mean PSA of 6. Patients were followed for an average of 63 months. Thirty-two patients (43%) developed metastasis, and 11 (15%) died of prostate cancer despite a negative post-radiation biopsy. Five of nine patients (56%) with sequential biopsies had a positive second biopsy. CONCLUSIONS: Patients with PSA recurrence and a negative post-radiation biopsy have a high chance of persistent local disease, progression, and death from prostate cancer. Furthermore, an initial negative biopsy does not rule-out local recurrence. Patients with biochemical recurrence after radiotherapy for prostate cancer need to be evaluated earlier for local recurrence.read more
Citations
More filters
Journal ArticleDOI
Detection of Recurrent Prostate Carcinoma with anti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and 111In–Capromab Pendetide SPECT/CT
David M. Schuster,Bital Savir-Baruch,Peter T. Nieh,Viraj A. Master,Raghuveer Halkar,Peter J. Rossi,Melinda M. Lewis,Jonathon A. Nye,Weiping Yu,F. DuBois Bowman,Mark M. Goodman +10 more
TL;DR: In this paper, the anti-1amino-3-fluorine 18fluorocyclobutane-1-carboxylic acid PET/CT is more sensitive than 111In-capromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma in the prostatic bed and extraprostatic sites.
Detection of Recurrent Prostate Carcinoma with anti -1-Amino-
David M. Schuster,Peter T. Nieh,Viraj A. Master,Raghuveer Halkar,Peter J. Rossi,Melinda M. Lewis,Jonathon A. Nye,Weiping Yu,F. DuBois Bowman,Mark M. Goodman +9 more
TL;DR: Anti-3-(18)F-FACBC PET/CT was more sensitive than (111)In-capromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease.
Journal ArticleDOI
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
Antoine Kass-iliyya,Gordana Jovic,Claire Murphy,Cyril Fisher,Isabel Syndikus,Chakiath C Jose,Christopher D Scrase,John Graham,David Nicol,Matthew R. Sydes,David P. Dearnaley +10 more
TL;DR: Two-year postradiotherapy prostate biopsies have limited value in patients with PSA control but both positive biopsy and higher PSA status are strongly associated with future bPFS events.
Journal ArticleDOI
Salvage of locally recurrent prostate cancer after definitive radiotherapy.
William M. Mendenhall,Randal H. Henderson,Bradford S. Hoppe,Romaine C. Nichols,Nancy P. Mendenhall +4 more
TL;DR: The 5-year biochemical progression-free survival rate is approximately 50% after salvage prostatectomy, however, the morbidity rate of the procedure is significantly higher compared with that observed in previously untreated patients.
Journal ArticleDOI
The real-time intraoperative guidance of the new HIFU Focal-One® platform allows to minimize the perioperative adverse events in salvage setting.
Enrico Checcucci,Enrico Checcucci,Stefano De Luca,Federico Piramide,Diletta Garrou,Alessandra Mosca,Andrea Galla,G. Belli,Filippo Russo,Pasquale Rescigno,Carlo Poti,Daniele Amparore,P. Verri,Gabriele Volpi,Matteo Manfredi,Cristian Fiori,Francesco Porpiglia +16 more
TL;DR: In this article, the authors evaluated the use of the Focal-One® HIFU platform in salvage setting to evaluate the occurrence of postoperative complications, including grade 2 complications and grade 3 complications.
References
More filters
Journal ArticleDOI
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach,Gerald E. Hanks,Howard D. Thames,Paul F. Schellhammer,William U. Shipley,Gerald H. Sokol,Howard M. Sandler +6 more
TL;DR: The panel recommended that investigators be allowed to use the ASTRO Consensus Definition after EBRT alone (no hormonal therapy) with strict adherence to guidelines as to "adequate follow-up."
Journal ArticleDOI
Consensus statement: Guidelines for PSA following radiation therapy
Journal ArticleDOI
High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer
Michael J. Zelefsky,Zvi Fuks,Margie Hunt,Henry J. Lee,Danna Lombardi,C. Clifton Ling,Victor E. Reuter,Ennapadam Venkatraman,Steven A. Leibel +8 more
TL;DR: Sophisticated conformal radiotherapy techniques with high dose 3-D conformal and intensity modulated radiation therapy improve the biochemical outcome in patients with favorable, intermediate and unfavorable risk prostate cancer.
Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy
JD Cox,M J Gallagher,E H Hammond,Richard Kaplan,PF Schellhammer,JM Crook,SA Leibel,JD Forman,PD Grimm,AL Zietman,MA Hudson,SA Schild,DC Beyer,DH Hussey,H Thames,W. U. Shipley +15 more
TL;DR: The panel judged that prostate re-biopsy is not necessary as standard follow-up care and that the absence of a rising PSA level after radiation therapy is the most rigorous end point of total tumor eradication.
Journal ArticleDOI
Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.
TL;DR: The American Society of Therapeutic Radiology and Oncology (ASTRO) challenged a multidisciplinary consensus panel to address consensus on specific issues in each of the two topics.